<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="98960">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01675258</url>
  </required_header>
  <id_info>
    <org_study_id>LSA003-HMO-CTIL</org_study_id>
    <nct_id>NCT01675258</nct_id>
  </id_info>
  <brief_title>Identifying Saliva Markers of Patients With Stomach, Colorectal (Including Pre-cancer Polyp) and Pancreatic Cancers</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Colorectal cancers account for 783,000 new cases and cause 437,000 deaths per year across
      the world. Diagnosis in the early stages improves survival rates. Up to now, these cancers
      are mostly diagnosed only at later stages of the disease's course through histoimmune
      staining and molecular biology processes on the tissues biopsied from the gastrointestinal
      system under invasive diagnostic procedures of colonoscopy.

      Oral fluid presents a large protein complexity and has been recently used as a diagnostic
      biofluid for oral, as well as systematic diseases. Using oral fluid as a bio-marker for the
      colorectal cancer can be advantageous as it contains gastrointestinal fluids, in addition to
      bacteria and bacteria lysate, which can also serve as a bio-markers' source for colorectal
      cancers. Proteomic technologies provide the tools needed to discover and identify
      disease-associated biomarkers.

      The aim of the present study is to identify salivary bio-markers in patients suffering from
      colorectal cancers.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2012</start_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Cross-Sectional</study_design>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Colorectal Cancer and Pre-cancer Polyps</condition>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Healthy adults above the age of 18 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study</arm_group_label>
    <description>Adult patients above the age of 18 years with gastric, colorectal (including pre-cancer polyps) or pancreatic cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Salivary samples</intervention_name>
    <description>Each participant will give a sample of saliva through spitting for 10 minutes in a sterile tube.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Study</arm_group_label>
    <other_name>Salivary Analysis</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole saliva
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients identified with gastric, colorectal (including pre-cancer polyps) or pancreatic
        cancer
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has not yet started treatment for the identified cancer

        Exclusion Criteria:

          -  medically compromised patients

          -  congenital syndromes

          -  being treated with radiotherapy or chemotherapy.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Moti Moskovitz, DMD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Medical Organization</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eyal Shtayer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Medical Organization</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Avi Levin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Medical Organization</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hadassah Medical Organization</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hadas Lemberg, PhD</last_name>
      <phone>0097226777572</phone>
      <email>lhadas@hadassah.org.il</email>
    </contact>
    <investigator>
      <last_name>Moti Moskovitz, DMD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <results_reference>
    <citation>Zhang L, Farrell JJ, Zhou H, Elashoff D, Akin D, Park NH, Chia D, Wong DT. Salivary transcriptomic biomarkers for detection of resectable pancreatic cancer. Gastroenterology. 2010 Mar;138(3):949-57.e1-7. Epub 2009 Nov 18.</citation>
    <PMID>19931263</PMID>
  </results_reference>
  <verification_date>July 2012</verification_date>
  <lastchanged_date>August 27, 2012</lastchanged_date>
  <firstreceived_date>August 27, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Polyps</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
